Our investment criteria is unique in the venture community. We believe in deep diligence and review nearly 1000+ companies each year, selecting only those that we believe in.

 
 
 

WHAT MATTERS TO US

Breadth of Application

Your breakthrough should have highly protectable IP and broad commercial applicability. We like technologies with many potential pathways.

 
 

Early in the Journey

A compelling paper or patent will spark our interest. Ideally we like to see a working proof of concept, but we will talk even before that.

the Right Individuals

We look for people who are responsive and curious, eager to engage and actively prepare for what’s ahead. We care about your future more than your past.

a mentorship Viewpoint

We invest early and stick around as long as needed. We aim to help our portfolio companies start off and end strong.

 
 

WHAT TO EXPECT

Interest Piqued

We take a first look at an innovation we encounter. We verify that it’s at an appropriate stage of development and that it has strong commercial potential.

 
 

Tell us more

Help us get to know the driving force supporting your innovation.  We have a defined set of questions for your company to answer, this helps us assess your product, business model and strategic goals.

 
 

Careful Study

We’ll learn everything we can about your innovation. We’ll read your papers, patents and summaries. We’ll ask questions and review our learnings with our broad, multi-displinary team to gather even more questions

 
 

In-Person Discussions

We don’t often get to this stage, but at this point we review your diligence package, visit you and have conversations about how together we all envision your breakthrough’s future.

 
 

Termsheets

If we are aligned, then we’ll prepare a termsheet that outlines the money we invest when your team meets well defined milestones.

 
 

OUR CRITERIA

 
  • Technology with a primary medical application.
  • Any technology except for a product considered a pharmaceutical by the FDA. We would definitely consider technologies for the pharmaceutical industry, such as manufacturing or clinical trial screening devices and tools.
  • The technology represents 10x magnitudes of improvement over current standard of care, or can enable a physician or patient or any other end user/customer to accomplish something that is not possible today.
  • The technology should translate into a revenue potential (and subsequent valuation) that can return the value of each fund ($50M valuation or more)
  • The technology has the potential to be used as a platform for multiple medical, and possibly non-medical, applications, with the accompanying IP that can be filed.
  • In addition to the technology areas, the opportunities that we are seeking are in an early stage of funding, seed round or earlier. Coming in as a lead investor is also ideal.
  • Specific examples of the type of innovations we are looking at include: molecular diagnostics, particularly for direct to consumer use, noninvasive imaging, noninvasive diagnostics and therapies for mental health, surgical tools, synthetic cardiovascular components.
 
 

interested in the deals we are currently reviewing?

 
 
 Zoic Capital at CDL-West in Vancouver, BC at the Sauder School of Business, University of British Columbia.

Zoic Capital at CDL-West in Vancouver, BC at the Sauder School of Business, University of British Columbia.